Literature DB >> 12617694

Role of pharmacogenomics in individualising treatment with SSRIs.

Dalu Mancama1, Robert W Kerwin.   

Abstract

The introduction of the SSRIs has significantly transformed the pharmacological treatment of a range of psychiatric disorders. In particular, individuals affected by depression, panic disorder, obsessive-compulsive disorder and social phobia have benefited substantially from their use. Compared with the previous generation of psychotropic drugs, SSRIs offer an improved tolerability to therapy while maintaining a high level of efficacy. Nevertheless, despite these advantages, not all patients benefit from treatment; an appreciable proportion do not respond adequately, while others may react adversely. This necessitates a review of the initial treatment choice, often involving extended periods of illness while a more suitable therapy is sought. Such a scenario could be avoided were it possible to determine the most suitable drug prior to treatment. Several factors are postulated to influence outcome of drug therapy; most recently, pharmacogenetic studies have demonstrated a significant influence of genetic mechanisms on the efficacy of clinically prescribed drugs. This contribution, which is primarily a reflection of alterations in genes that encode drug-metabolising enzymes, drug receptors, transporters and second messengers, may be pertinent to the success of SSRI therapy. Attesting to this potential, studies to elucidate the influence of genetic processes on SSRI efficacy now represent a major focus of pharmacogenetics research. Current evidence emerging from the field suggests that gene variants within the serotonin transporter and cytochrome P450 drug-metabolising enzymes may bear a particular importance, though further corroboration of these findings is still warranted. At the same time, it appears likely that further key participating genes remain to be identified. By comprehensively delineating these genetic components, it is envisaged that this will eventually facilitate the development of highly sensitive protocols for individualising SSRI treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12617694     DOI: 10.2165/00023210-200317030-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  75 in total

1.  Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.

Authors:  Z H Xu; W Wang; X J Zhao; S L Huang; B Zhu; N He; Y Shu; Z Q Liu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.

Authors:  B G Pollock; R E Ferrell; B H Mulsant; S Mazumdar; M Miller; R A Sweet; S Davis; M A Kirshner; P R Houck; J A Stack; C F Reynolds; D J Kupfer
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

Review 3.  Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I.

Authors:  A T Harvey; S H Preskorn
Journal:  J Clin Psychopharmacol       Date:  1996-08       Impact factor: 3.153

Review 4.  Selective serotonin reuptake inhibitors: infrequent medical adverse effects.

Authors:  R J Goldberg
Journal:  Arch Fam Med       Date:  1998 Jan-Feb

5.  Serotonin transporter gene polymorphism and antidepressant response.

Authors:  D K Kim; S W Lim; S Lee; S E Sohn; S Kim; C G Hahn; B J Carroll
Journal:  Neuroreport       Date:  2000-01-17       Impact factor: 1.837

6.  Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro.

Authors:  K Kobayashi; T Ishizuka; N Shimada; Y Yoshimura; K Kamijima; K Chiba
Journal:  Drug Metab Dispos       Date:  1999-07       Impact factor: 3.922

Review 7.  Pharmacogenetics and the serotonin system: initial studies and future directions.

Authors:  J Veenstra-VanderWeele; G M Anderson; E H Cook
Journal:  Eur J Pharmacol       Date:  2000-12-27       Impact factor: 4.432

8.  Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

Authors:  J H Wang; Z Q Liu; W Wang; X P Chen; Y Shu; N He; H H Zhou
Journal:  Clin Pharmacol Ther       Date:  2001-07       Impact factor: 6.875

9.  Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice.

Authors:  A J Mayorga; A Dalvi; M E Page; S Zimov-Levinson; R Hen; I Lucki
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

10.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.

Authors:  M Nakajima; T Yokoi; M Mizutani; M Kinoshita; M Funayama; T Kamataki
Journal:  J Biochem       Date:  1999-04       Impact factor: 3.387

View more
  9 in total

Review 1.  [Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

2.  Increase the dose or give it a few more weeks.

Authors:  Michael S Hanau
Journal:  Psychiatry (Edgmont)       Date:  2007-03

Review 3.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Resolution of Pathological Skin Picking With Fluvoxamine in a 74-Year-Old Dementia Patient.

Authors:  Zeba Hasan Hafeez
Journal:  Prim Care Companion CNS Disord       Date:  2016-01-28

Review 5.  Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.

Authors:  Katherine I Morley; Wayne D Hall
Journal:  J Mol Med (Berl)       Date:  2003-11-04       Impact factor: 4.599

Review 6.  From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes.

Authors:  Alessandro Serretti; Paola Artioli
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

Review 7.  Treatments in depression.

Authors:  Fabrice Duval; Barry D Lebowitz; Jean-Paul Macher
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 8.  Pharmacogenomics in depression and antidepressants.

Authors:  Brigitta Bondy
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

9.  Candidate genes for antidepressant response to selective serotonin reuptake inhibitors.

Authors:  Francis E Lotrich; Bruce G Pollock
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.